Abstract
Angioedema is an uncommon, yet morbid, adverse reaction to recombinant tissue plasminogen activator (rtPA) administration for ischemic stroke. Orolingual edema may preclude completion of rtPA therapy and cause potential airway compromise. Few case reports and case series have examined the incidence of angioedema and anaphylaxis related to this common stroke therapy. We report a case of orolingual edema and bleeding in a patient who received rtPA for acute ischemic stroke who was concurrently on an angiotension-converting enzyme inhibitor and discuss the pathophysiology of this reaction.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 691-693 |
| Number of pages | 3 |
| Journal | American journal of therapeutics |
| Volume | 20 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jan 1 2013 |
Keywords
- ACE-inhibitors and rt-PAinteraction
- Angioedema
- Orolingual edema
- Rt-PA adverse reaction
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Angioedema from recombinant TPA administration: Case report and pathophysiology review'. Together they form a unique fingerprint.
Cite this
Foster-Goldman, A., & McCarthy, D. (2013). Angioedema from recombinant TPA administration: Case report and pathophysiology review. American journal of therapeutics, 20(6), 691-693. https://doi.org/10.1097/MJT.0b013e3182799083